METiS Pharmaceuticals and Eli Lilly Strike AI-LNP Delivery Collaboration Worth Up to 1.1 Billion Dollars

METiS Pharmaceuticals (7666.HK) announced on October 19, 2026 a strategic collaboration with Eli Lilly and Company on novel LNP delivery solutions. The agreement includes an upfront payment of over ten million US dollars and milestone payments of up to 1.1 billion US dollars. The collaboration is based on METiS's AiLNP platform under its NanoForge system, exploring tissue-specific delivery technologies suited to multiple therapeutic modalities.